First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of First Tracks Biotherapeutics (NASDAQ:TRAX) have been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $40.00.

Several research firms have recently weighed in on TRAX. Leerink Partners initiated coverage on shares of First Tracks Biotherapeutics in a research note on Friday, April 24th. They issued an “outperform” rating and a $46.00 price objective for the company. Barclays started coverage on First Tracks Biotherapeutics in a research report on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 price objective for the company. UBS Group assumed coverage on First Tracks Biotherapeutics in a research report on Tuesday, April 21st. They issued a “buy” rating and a $45.00 target price on the stock. Piper Sandler started coverage on First Tracks Biotherapeutics in a report on Monday, May 4th. They set an “overweight” rating and a $54.00 price target for the company. Finally, HC Wainwright lifted their price objective on First Tracks Biotherapeutics from $30.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday.

First Tracks Biotherapeutics Trading Up 11.9%

Shares of TRAX traded up $3.84 during midday trading on Friday, reaching $36.24. 1,919,842 shares of the stock were exchanged, compared to its average volume of 594,693. The stock has a market capitalization of $1.26 billion and a P/E ratio of -19.70. The firm has a 50 day moving average of $18.46. First Tracks Biotherapeutics has a twelve month low of $14.72 and a twelve month high of $38.49.